ALK and lung carcinoma: Another retrospective study from 2021 with 83 patients diagnosed with ALK-positive lung cancer mostly treated with single-agent immunotherapy described a median time to treatment discontinuation of 2.17 months [16], an outcome that is consistent with our pre-ABCP experience.